Efficacy and Safety of Long Acting Beraprost (TRK-100STP) for Lumbar Spinal Canal Stenosis with Intermittent Claudication: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Trial Profile

Efficacy and Safety of Long Acting Beraprost (TRK-100STP) for Lumbar Spinal Canal Stenosis with Intermittent Claudication: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2012

At a glance

  • Drugs Beraprost (Primary)
  • Indications Embolism and thrombosis; Intermittent claudication; Spinal stenosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Kaken Pharmaceutical
  • Most Recent Events

    • 12 Oct 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 16 Nov 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 11 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top